The UK has become the first country in the world to approve CRISPR gene-editing therapy. The landmark biotech decision involves the treatment of two specific blood dieseases, but also opens the door for the use of the technology in treating many other genetic disorders. Regulators approved the use of CRISPR for the treatment of inherited diseases sickle-cell anaemia and β-thalassaemia on Thursday. The former affects the shape of red blood cells of 20 million people worldwide and can cause debilitating pain. People with the latter need to receive regular blood transfusions to counteract a reduced production of haemoglobin, which in…
This story continues at The Next Web
from The Next Web https://ift.tt/9nBgpcy
Comments
Post a Comment